ProStrakan Group received approval from the FDA for Sancuso (Granisetron Transdermal System), the first patch to provide five days of control of nausea and vomiting for patients undergoing chemotherapy.     Chemotherapy-induced nausea and vomiting (CINV) is common among patients undergoing chemotherapy and can lead to dehydration, malnutrition, treatment delay, or even discontinuation of treatment.     Sancuso is a transdermal patch that delivers granisetron through a thin layer of adhesiv...